Results 201 to 210 of about 35,110 (216)

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

Lancet, The, 2019
Hisham Mehanna, Max Robinson, Andrew Hartley   +2 more
exaly  

Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

New England Journal of Medicine, 2008
Jacob D Hosen, Thomas A E Platts-Mills
exaly  

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

New England Journal of Medicine, 2009
György Bodoky, Gunnar Folprecht
exaly  

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Lancet, The, 2009
Robert Pirker, Maciej Krzakowski, Rodryg Adam Ramlau   +2 more
exaly  

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

2023
Zetong Ma, Changhai Lei, Shi Hu
openaire   +1 more source

Cetuximab dosing by rash—is the scaling of EVEREST meaningful?

Nature Reviews Clinical Oncology, 2012
Sebastian Stintzing
exaly  

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Lancet, The, 2011
Timothy S Maughan, Richard H Wilson, David J Fisher   +2 more
exaly  

Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck

Nature Reviews Clinical Oncology, 2009
William N William
exaly  

Cetuximab for the Treatment of Colorectal Cancer

New England Journal of Medicine, 2007
Christos S Karapetis, Dongsheng Tu, Timothy Price   +2 more
exaly  

Cetuximab

Nature Reviews Drug Discovery, 2005
Richard Goldberg
exaly